Showing results (71-80 of 80) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
A reversed sulfonamide series of selective RORc inverse agonistsMonique B van Niel, Benjamin P Fauber, Matthew Cartwright, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.Bioorganic & Medicinal Chemistry Letters|April 27, 2023
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug designJames J Crawford, Jianwen Feng, Hans D Brightbill, et al.Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.Nature|March 4, 2011
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Ingrid E Wertz, Saritha Kusam, Cynthia Lam, et al.ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisMark E Schnute, Patrick M O'Brien, Joe Nahra, et al.Nature Communications|January 14, 2018
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosusHans D Brightbill, Eric Suto, Nicole Blaquiere, et al.Journal of Medicinal Chemistry|March 3, 2024
Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory DiseaseJack A Terrett, Justin Q Ly, Paula Katavolos, et al.Pageof 8